CN114038496B - Relative risk evaluation method for drinking water source water body antibiotic resistance gene - Google Patents

Relative risk evaluation method for drinking water source water body antibiotic resistance gene Download PDF

Info

Publication number
CN114038496B
CN114038496B CN202111315456.3A CN202111315456A CN114038496B CN 114038496 B CN114038496 B CN 114038496B CN 202111315456 A CN202111315456 A CN 202111315456A CN 114038496 B CN114038496 B CN 114038496B
Authority
CN
China
Prior art keywords
args
arbs
abundance
relative
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111315456.3A
Other languages
Chinese (zh)
Other versions
CN114038496A (en
Inventor
蒋鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan University
Original Assignee
Sichuan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan University filed Critical Sichuan University
Priority to CN202111315456.3A priority Critical patent/CN114038496B/en
Publication of CN114038496A publication Critical patent/CN114038496A/en
Application granted granted Critical
Publication of CN114038496B publication Critical patent/CN114038496B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0635—Risk analysis of enterprise or organisation activities
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for specific business sectors, e.g. utilities or tourism
    • G06Q50/02—Agriculture; Fishing; Mining
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A20/00—Water conservation; Efficient water supply; Efficient water use
    • Y02A20/152—Water filtration

Abstract

The invention discloses a drinking water source water body antibiotic resistance gene relative risk evaluation method, which comprises the steps of preprocessing the abundance of ARGs and the abundance of ARBs in a drinking water source water body, arranging the ARGs and the abundance of ARBs into a data set, carrying out scaling processing on the data set to realize data standardization, endowing different risk coefficients for the ARGs and the ARBs of different types, respectively calculating the total risk score of the ARGs and the ARBs, fully considering the heterogeneity of the ARGs and the ARBs of different types, further limiting the proportion of risks according to the relative weight of the total risk score of the ARGs and the total risk score of the ARBs, finally obtaining the antibiotic resistance relative risk score, and realizing accurate evaluation of the antibiotic resistance gene relative risk in the drinking water source water body.

Description

Relative risk evaluation method for antibiotic resistance genes in drinking water source water body
Technical Field
The invention relates to the field of evaluating the risk of antibiotic resistance genes in a drinking water source water body, in particular to a relative risk evaluation method of the antibiotic resistance genes in the drinking water source water body.
Background
Due to the abuse of antibiotics in the industries of animal husbandry, aquaculture and the like, Antibiotic Resistance Genes (ARGs) are induced in part of bacteria, and then the Antibiotic Resistance Bacteria (ARBs) generate drug resistance to the corresponding antibiotics. ARGs and ARBs in aquatic environments pose considerable potential risks to the ecological environment and human health, and these emerging environmental pollutants have attracted global attention in recent years. The total amount of the antimicrobial drugs for edible animals in China is the first global, and the related health problems caused by antibiotics and ARGs are particularly serious in China. Therefore, designing the ARGs potential risk evaluation for active risk management and control and the space-time visualization thereof are particularly urgent.
The traditional risk evaluation method of the environmental pollutants mainly comprises a toxicity low-medium value method, a toxicity equivalent method, a risk quotient method, a quantitative risk evaluation method and the like. However, the knowledge of the dose effect related to the ARGs (i.e. the quantitative correlation between the dose of the ARGs acting on a living body and the degree of the specific biological effect of an individual) is still lacking, so that the methods cannot be applied to the risk assessment of the ARGs, and the estimation of the spatiotemporal relativity of the potential risk of the ARGs is a way to save the country with a curve under the current conditions. The types of the ARGs and the ARBs are various, and heterogeneity exists among different ARGs and different ARBs in the drinking water source water body. In the existing literature, a relative risk evaluation integration method considering heterogeneity of different types of ARGs and ARBs has not been constructed.
Disclosure of Invention
Aiming at the defects in the prior art, the relative risk evaluation method for the antibiotic resistance genes of the drinking water source water body solves the problem that a relative risk evaluation method considering the heterogeneity of different types of ARGs and ARBs is lacked in the prior art.
In order to achieve the purpose of the invention, the invention adopts the technical scheme that: a relative risk evaluation method for drinking water source water body antibiotic resistance genes comprises the following steps:
s1, preprocessing the abundance of the ARGs and the abundance of the ARBs in the drinking water source water body to obtain an ARGs group sample data set and an ARBs group sample data set;
s2, carrying out data scaling processing on the ARGs group sample data set and the ARBs group sample data set to obtain an ARGs abundance scaling value and an ARBs abundance scaling value;
and S3, calculating an antibiotic resistance relative risk score according to the ARGs abundance scaling value and the ARBs abundance scaling value.
Further, the step S1 includes the following sub-steps:
s11, converting the abundance of the ARGs in the drinking water source water body into the relative abundance of the ARGs;
s12, converting the abundance of the ARBs in the drinking water source water body into the relative abundance of the ARBs;
s13, constructing the relative abundance of the ARGs into a group of sample data with K elements, namely an ARGs group sample data set;
s14, constructing the relative abundance of the ARBs into a group of sample data with K elements, namely an ARBs group of sample data set.
Further, the formula for performing data scaling processing on the ARGs group sample data set and the ARBs group sample data set in step S2 is as follows:
Figure BDA0003343466890000021
Figure BDA0003343466890000022
wherein the content of the first and second substances,
Figure BDA0003343466890000023
sample data set F for ARBs groupARBRelative abundance data for ARBs of class m
Figure BDA0003343466890000024
The value of the scaling of the abundance of (c),
Figure BDA0003343466890000025
sample data set F for ARGs groupsARGRelative abundance data of middle nth ARGs
Figure BDA0003343466890000026
Abundance of (c) scaling value, max (F)ARB) Sample data set F for ARBs groupARBMaximum of relative abundance data of middle ARBs, min (F)ARB) Sample data set F for ARBs groupARBMinimum of relative abundance data, max (F) for ARBs in middleARG) Sample data set F for ARGs groupsARGMaximum value of relative abundance data of middle ARGs, min (F)ARG) Sample data set F for ARGs groupsARGRelative abundance data for medium ARGs.
Further, the step S3 includes the following sub-steps:
s31, carrying out risk assignment on the scaling values of the ARGs abundance and the scaling values of the ARBs abundance to obtain the risk scores of the ARGs and the risk scores of the ARBs;
s32, calculating the total risk score of the ARGs and the total risk score of the ARBs according to the risk score of the ARGs and the risk score of the ARBs;
s33, carrying out normalization processing on the total risk scores of the ARGs and the total risk scores of the ARBs;
and S34, calculating an antibiotic resistance relative risk score according to the relative weight of the normalized ARGs total risk score and the ARBs total risk score.
The beneficial effects of the above further scheme are: in the risk assignment process, the heterogeneity of different types of ARGs and ARBs can be effectively considered by means of the macro gene database and the disability adjusting life year database, and the relative risks of the respective parts of the ARGs and the ARBs are respectively integrated. The ARGs total risk scores and the ARBs total risk scores have different magnitude scales, and the ARGs total risk scores and the ARBs total risk scores are normalized so as to facilitate the integration of two subsequent parts and the calculation of a final total relative risk value.
Further, the formula for performing risk assignment on the ARGs abundance scaling values and ARBs abundance scaling values in step S31 is as follows:
Figure BDA0003343466890000031
Figure BDA0003343466890000032
wherein the content of the first and second substances,
Figure BDA0003343466890000033
risk scores for scaled values of abundance of class m ARBs,
Figure BDA0003343466890000034
risk factors for scaled values of abundance of class m ARBs,
Figure BDA0003343466890000035
risk scores that scale for the abundance of the nth class of ARGs,
Figure BDA0003343466890000036
risk factors for the abundance scaling values of the nth class of ARGs,
Figure BDA0003343466890000037
sample data set F for ARBs groupARBRelative abundance data for ARBs of class m
Figure BDA0003343466890000041
The value of the scaling of the abundance of (c),
Figure BDA0003343466890000042
sample data set F for ARGs groupsARGRelative abundance data of middle nth ARGs
Figure BDA0003343466890000043
Scaling the value of abundance of (c).
The beneficial effects of the above further scheme are: relative abundance data for different classes of ARBs
Figure BDA0003343466890000044
Abundance scaling values and relative abundance data for different classes of ARGs
Figure BDA0003343466890000045
The abundance scaling values of (a) give different risk factors, fully taking into account the heterogeneity of different species of ARGs and ARBs.
Further, the formula for calculating the total risk scores of the ARGs and the total risk scores of the ARBs in step S32 is as follows:
Figure BDA0003343466890000046
Figure BDA0003343466890000047
wherein S isARBScore for total risk of ARBs, SARGIs the total risk score of the ARGs, M is the number of categories of the ARBs, N is the number of categories of the ARGs,
Figure BDA0003343466890000048
risk scores for scaled values of abundance of class m ARBs,
Figure BDA0003343466890000049
risk score for nth class ARGs abundance scale values.
Further, the formula for calculating the relative risk score of antibiotic resistance in step S34 is as follows:
Figure BDA00033434668900000410
wherein the content of the first and second substances,
Figure BDA00033434668900000411
alpha is the relative weight of the normalized total risk score of ARBs and the normalized total risk score of ARGs,
Figure BDA00033434668900000412
to be the normalized total risk score of ARBs,
Figure BDA00033434668900000413
is a normalized ARGs total risk score.
The beneficial effects of the above further scheme are: the step can effectively integrate the knowledge and experience of experts in the field of antibiotic resistance gene risk management, organically integrate the total scores of the ARGs and the total scores of the ARBs, and finally give the total score of antibiotic resistance relative risk.
In conclusion, the beneficial effects of the invention are as follows: according to the method, the abundance of the ARGs and the abundance of the ARBs in the drinking water source water body are preprocessed and arranged into a data set, the data set is zoomed, the standardization of the data is realized, different risk coefficients are given to the ARGs and the ARBs in different types, the total risk scores of the ARGs and the ARBs are calculated respectively, the heterogeneity of the ARGs and the ARBs in different types is fully considered by the total risk score, the proportion of risks is further limited according to the relative weight of the total risk score of the ARGs and the total risk score of the ARBs, the relative risk score of antibiotic resistance is finally obtained, and the accurate evaluation of the relative risk of the antibiotic resistance genes in the drinking water source water body is realized.
Drawings
FIG. 1 is a flow chart of a relative risk evaluation method of antibiotic resistance genes in a drinking water source water body.
Detailed Description
The following description of the embodiments of the present invention is provided to facilitate the understanding of the present invention by those skilled in the art, but it should be understood that the present invention is not limited to the scope of the embodiments, and it will be apparent to those skilled in the art that various changes may be made without departing from the spirit and scope of the invention as defined and defined in the appended claims, and all matters produced by the invention using the inventive concept are protected.
As shown in figure 1, the relative risk evaluation method of the antibiotic resistance gene of the drinking water source water body comprises the following steps:
s1, preprocessing the abundance of the ARGs and the abundance of the ARBs in the drinking water source water body to obtain an ARGs group sample data set and an ARBs group sample data set;
the step S1 includes the following sub-steps:
s11, converting the abundance of the ARGs in the drinking water source water body into the relative abundance of the ARGs;
at step S11, the relative abundance of ARGs ═ ARGs abundance/16S rRNA abundance, i.e., ARGs abundance is converted into ARGs relative abundance by 16S ribosomal RNA (16S rRNA).
S12, converting the abundance of the ARBs in the drinking water source water body into the relative abundance of the ARBs;
s13, constructing the relative abundance of the ARGs into a group of sample data with K elements, namely an ARGs group sample data set;
s14, constructing the relative abundance of the ARBs into a group of sample data with K elements, namely an ARBs group of sample data set.
S2, carrying out data scaling processing on the ARGs group sample data set and the ARBs group sample data set to obtain an ARGs abundance scaling value and an ARBs abundance scaling value;
raw abundance data for each ARB or ARG due to the different range of values for different ARBs (or different ARGs)
Figure BDA0003343466890000061
And
Figure BDA0003343466890000062
wherein M belongs to {1,2, …, M }, M is the category of ARBs,n ∈ {1,2, …, N }, N being the kind of ARGs, scaled by min-max normalization.
The formula for performing data scaling processing on the ARGs group sample data set and the ARBs group sample data set in step S2 is as follows:
Figure BDA0003343466890000063
Figure BDA0003343466890000064
wherein the content of the first and second substances,
Figure BDA0003343466890000065
sample data set F for ARBs groupARBRelative abundance data for ARBs of class m
Figure BDA0003343466890000066
The value of the scaling of the abundance of (c),
Figure BDA0003343466890000067
sample data set F for ARGs groupsARGRelative abundance data of middle nth ARGs
Figure BDA0003343466890000068
Abundance of (c) scaling value, max (F)ARB) Sample data set F for ARBs groupARBMaximum of relative abundance data of middle ARBs, min (F)ARB) Sample data set F for ARBs groupARBMinimum of relative abundance data, max (F) for ARBs in middleARG) Sample data set F for ARGs groupsARGMaximum value of relative abundance data of middle ARGs, min (F)ARG) Sample data set F for ARGs groupsARGThe minimum of relative abundance data of middle ARGs,
Figure BDA0003343466890000069
s3, calculating the relative risk score of antibiotic resistance according to the ARGs abundance scaling value and the ARBs abundance scaling value;
obtaining relative risk coefficients of different ARBs from a DALYs database and an ARG ranker database respectively
Figure BDA0003343466890000071
(i.e., relative risk rating) and relative risk factors of different ARGs
Figure BDA0003343466890000072
Scaling the abundance by a value
Figure BDA0003343466890000073
And
Figure BDA0003343466890000074
weighting and adding by risk coefficient to obtain different ARBs risk scores
Figure BDA0003343466890000075
And different ARGs risk scores
Figure BDA0003343466890000076
The step S3 includes the following sub-steps:
s31, carrying out risk assignment on the scaling values of the ARGs abundance and the scaling values of the ARBs abundance to obtain the risk scores of the ARGs and the risk scores of the ARBs;
the formula for performing risk assignment on the ARGs abundance scaling values and ARBs abundance scaling values in step S31 is as follows:
Figure BDA0003343466890000077
Figure BDA0003343466890000078
wherein the content of the first and second substances,
Figure BDA0003343466890000079
risk scores for scaled values of abundance of class m ARBs,
Figure BDA00033434668900000710
risk factors for scaled values of abundance of class m ARBs,
Figure BDA00033434668900000711
risk scores that scale for the abundance of the nth class of ARGs,
Figure BDA00033434668900000712
risk factors for the abundance scaling values of the nth class of ARGs,
Figure BDA00033434668900000713
sample data set F for ARBs groupARBRelative abundance data of ARBs of class m
Figure BDA00033434668900000714
The value of the scaling of the abundance of (c),
Figure BDA00033434668900000715
sample data set F for the ARGs groupARGRelative abundance data of middle nth ARGs
Figure BDA00033434668900000716
Scaling the value of abundance of (c).
S32, calculating the total risk score of the ARGs and the total risk score of the ARBs according to the risk score of the ARGs and the risk score of the ARBs;
the formula for calculating the total risk scores of the ARGs and the ARBs in step S32 is as follows:
Figure BDA00033434668900000717
Figure BDA00033434668900000718
wherein S isARBScore for total risk of ARBs, SARGIs the total risk score of the ARGs, M is the number of categories of the ARBs, N is the number of categories of the ARGs,
Figure BDA0003343466890000081
risk scores for scaled values of abundance of class m ARBs,
Figure BDA0003343466890000082
risk score for nth class ARGs abundance scale values.
S33, carrying out normalization processing on the total risk scores of the ARGs and the total risk scores of the ARBs; in order to integrate the two parts of the ARBs and the ARGs total risk scores, the ARBs total risk scores and the ARGs total risk scores are normalized respectively by adopting minimum and maximum normalization on the basis of not influencing the relativity of final scores.
And S34, calculating an antibiotic resistance relative risk score according to the relative weight of the normalized ARGs total risk score and the ARBs total risk score.
Since vectors for ARBs are considered endpoints of antibiotic resistance transmission pathways, ARBs are given greater weight and then scored according to the normalized total risk of ARBs
Figure BDA0003343466890000083
And normalizing the ARGs total risk score
Figure BDA0003343466890000084
The weighted integrated antibiotic Resistance (AMR) relative risk score can be expressed as
Figure BDA0003343466890000085
The formula for calculating the antibiotic resistance relative risk score in step S34 is:
Figure BDA0003343466890000086
wherein the content of the first and second substances,
Figure BDA0003343466890000087
is antibiotic resistance relativeA risk score, a is the relative weight of the normalized ARBs total risk score to the normalized ARGs total risk score,
Figure BDA0003343466890000088
to be the normalized total risk score of ARBs,
Figure BDA0003343466890000089
is a normalized ARGs total risk score.

Claims (4)

1. A relative risk evaluation method for an antibiotic resistance gene of a drinking water source water body is characterized by comprising the following steps:
s1, preprocessing the abundance of the ARGs and the abundance of the ARBs in the drinking water source water body to obtain an ARGs group sample data set and an ARBs group sample data set;
step S1 includes the following substeps:
s11, converting the abundance of the ARGs in the drinking water source water body into the relative abundance of the ARGs;
s12, converting the abundance of the ARBs in the drinking water source water body into the relative abundance of the ARBs;
s13, constructing the relative abundance of the ARGs into a group of sample data with K elements, namely an ARGs group sample data set;
s14, constructing the relative abundance of the ARBs into a group of sample data with K elements, namely an ARBs group sample data set;
s2, carrying out data scaling processing on the ARGs group sample data set and the ARBs group sample data set to obtain an ARGs abundance scaling value and an ARBs abundance scaling value;
in step S2, the formula for performing data scaling processing on the ARGs group sample data set and the ARBs group sample data set is as follows:
Figure FDA0003602863920000011
Figure FDA0003602863920000012
wherein the content of the first and second substances,
Figure FDA0003602863920000013
sample data set F for ARBs groupARBRelative abundance data for ARBs of class m
Figure FDA0003602863920000014
The value of the scaling of the abundance of (c),
Figure FDA0003602863920000015
sample data set F for ARGs groupsARGRelative abundance data of middle nth ARGs
Figure FDA0003602863920000016
Abundance of (c) scaling value, max (F)ARB) Sample data set F for ARBs groupARBMaximum of relative abundance data of middle ARBs, min (F)ARB) Sample data set F for ARBs groupARBMinimum of relative abundance data, max (F) for ARBs in middleARG) Sample data set F for ARGs groupsARGMaximum value of relative abundance data of middle ARGs, min (F)ARG) Sample data set F for ARGs groupsARGMinimum of relative abundance data for middle ARGs;
s3, calculating the relative risk score of antibiotic resistance according to the scaling values of the abundance of the ARGs and the abundance of the ARBs;
step S3 includes the following substeps:
s31, carrying out risk assignment on the scaling values of the ARGs abundance and the scaling values of the ARBs abundance to obtain the risk scores of the ARGs and the risk scores of the ARBs;
s32, calculating the total risk score of the ARGs and the total risk score of the ARBs according to the risk score of the ARGs and the risk score of the ARBs;
s33, carrying out normalization processing on the total risk scores of the ARGs and the total risk scores of the ARBs;
and S34, calculating an antibiotic resistance relative risk score according to the relative weight of the normalized ARGs total risk score and the ARBs total risk score.
2. The method for evaluating the relative risk of the antibiotic resistance genes in the drinking water source body as claimed in claim 1, wherein the risk assignment formula for the scaled values of the abundance of ARGs and the scaled values of the abundance of ARBs in step S31 is as follows:
Figure FDA0003602863920000021
Figure FDA0003602863920000022
wherein the content of the first and second substances,
Figure FDA0003602863920000023
risk scores for scaled values of abundance of class m ARBs,
Figure FDA0003602863920000024
risk factors for the scaled abundance of ARBs of class m,
Figure FDA0003602863920000025
risk scores that scale for the abundance of the nth class of ARGs,
Figure FDA0003602863920000026
risk factors for the abundance scaling values of the nth class of ARGs,
Figure FDA0003602863920000027
sample data set F for ARBs groupARBRelative abundance data for ARBs of class m
Figure FDA0003602863920000028
The value of the scaling of the abundance of (c),
Figure FDA0003602863920000029
sample data set F for ARGs groupsARGMiddle nth ARGs phaseFor abundance data
Figure FDA00036028639200000210
Scaling the value of abundance of (c).
3. The drinking water source water body antibiotic resistance gene relative risk evaluation method of claim 1, wherein the formula for calculating the total risk scores of the ARGs and the ARBs in the step S32 is as follows:
Figure FDA0003602863920000031
Figure FDA0003602863920000032
wherein S isARBScore for total risk of ARBs, SARGIs the total risk score of ARGs, M is the number of categories of ARBs, N is the number of categories of ARGs,
Figure FDA0003602863920000033
risk scores for scaled values of abundance of class m ARBs,
Figure FDA0003602863920000034
risk score for nth class ARGs abundance scale values.
4. The drinking water source water body antibiotic resistance gene relative risk evaluation method according to claim 1, wherein the formula for calculating the antibiotic resistance relative risk score in the step S34 is as follows:
Figure FDA0003602863920000035
wherein the content of the first and second substances,
Figure FDA0003602863920000036
alpha is the relative weight of the normalized total risk score of ARBs and the normalized total risk score of ARGs,
Figure FDA0003602863920000037
are normalized total risk scores for ARBs,
Figure FDA0003602863920000038
is a normalized ARGs total risk score.
CN202111315456.3A 2021-11-08 2021-11-08 Relative risk evaluation method for drinking water source water body antibiotic resistance gene Active CN114038496B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111315456.3A CN114038496B (en) 2021-11-08 2021-11-08 Relative risk evaluation method for drinking water source water body antibiotic resistance gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111315456.3A CN114038496B (en) 2021-11-08 2021-11-08 Relative risk evaluation method for drinking water source water body antibiotic resistance gene

Publications (2)

Publication Number Publication Date
CN114038496A CN114038496A (en) 2022-02-11
CN114038496B true CN114038496B (en) 2022-06-03

Family

ID=80136728

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111315456.3A Active CN114038496B (en) 2021-11-08 2021-11-08 Relative risk evaluation method for drinking water source water body antibiotic resistance gene

Country Status (1)

Country Link
CN (1) CN114038496B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115496618A (en) * 2022-09-09 2022-12-20 长江水利委员会长江科学院 Method for estimating abundance and distribution characteristics of antibiotic resistance genes of lake and reservoir surface sediments

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018206013A1 (en) * 2017-01-09 2019-07-25 Spokade Holdings Pty Ltd Methods and systems for monitoring bacterial ecosystems and providing decision support for antibiotic use
CN110776078A (en) * 2019-10-24 2020-02-11 同济大学 Advanced treatment method of antibiotic resistance gene in sewage
CN112116258A (en) * 2020-09-22 2020-12-22 中国环境科学研究院 Method for evaluating risk of mobile source of emergency environment event of drinking water source
WO2021024178A2 (en) * 2019-08-05 2021-02-11 Tata Consultancy Services Limited System and method for risk assessment of multiple sclerosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113611357A (en) * 2020-11-17 2021-11-05 上海美吉生物医药科技有限公司 Resistance gene analysis method, device, medium and terminal based on metagenome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018206013A1 (en) * 2017-01-09 2019-07-25 Spokade Holdings Pty Ltd Methods and systems for monitoring bacterial ecosystems and providing decision support for antibiotic use
WO2021024178A2 (en) * 2019-08-05 2021-02-11 Tata Consultancy Services Limited System and method for risk assessment of multiple sclerosis
CN110776078A (en) * 2019-10-24 2020-02-11 同济大学 Advanced treatment method of antibiotic resistance gene in sewage
CN112116258A (en) * 2020-09-22 2020-12-22 中国环境科学研究院 Method for evaluating risk of mobile source of emergency environment event of drinking water source

Also Published As

Publication number Publication date
CN114038496A (en) 2022-02-11

Similar Documents

Publication Publication Date Title
CN107680082A (en) Lung tumor identification method based on depth convolutional neural networks and global characteristics
CN114038496B (en) Relative risk evaluation method for drinking water source water body antibiotic resistance gene
de Jonge et al. Housefly (Musca domestica L.) associated microbiota across different life stages
Rosa Junior et al. Fumonisin production by Fusarium verticillioides in maize genotypes cultivated in different environments
Zhao et al. Genomic scan for selection signature reveals fat deposition in Chinese indigenous sheep with extreme tail types
Xu et al. Dynamic assessment of water quality based on a variable fuzzy pattern recognition model
Suzuki et al. Low toxicity of deoxynivalenol-3-glucoside in microbial cells
Forcellini et al. Microhabitat selection by macroinvertebrates: generality among rivers and functional interpretation
Hannan et al. Classification and prediction of fecal coliform in stream waters using decision trees (DTs) for upper Green River watershed, Kentucky, USA
Boath et al. Polyphasic characterisation of Cedecea colo sp. nov., a new enteric bacterium isolated from the koala hindgut
Getahun et al. Molecular genetic diversity and population structure in Ethiopian chickpea germplasm accessions
Labuce et al. Environmental impacts on zooplankton functional diversity in brackish semi-enclosed gulf
Kurniawati et al. Isolation and identification of lactose-degrading yeasts and characterisation of their fermentation-related ability to produce ethanol
Sbardella et al. Genome-wide association study provides insights into important genes for reproductive traits in Nelore cattle
Forsythe et al. Microbial isolates with Anti-Pseudogymnoascus destructans activities from Western Canadian bat wings
Liu et al. Health status assessment of diesel engine valve clearance based on BFA-BOA-VMD adaptive noise reduction and multi-channel information fusion
Cui et al. Diaporthe taoicola and D. siamensis, Two New Records on Citrus sinensis in China
Guinto et al. Conservation genetic analysis of Blanding’s Turtles across Ohio, Indiana, and Michigan
Li et al. Initial spore density has an influence on ochratoxin A content in Aspergillus ochraceus CGMCC 3.4412 in PDB and its interaction with seeds
Agha et al. Genetic analysis of novel behaviour traits in pigs derived from social network analysis
Qiu et al. The Effects of Water Level Fluctuation on Zooplankton Communities in Shahu Lake Based on DNA Metabarcoding and Morphological Methods
Shams et al. Multiple lines of evidence indicate limited natural recruitment of golden perch (Macquaria ambigua) in the Highly Regulated Lachlan River
Chertoptud et al. Microcrustaceans (Cladocera and Copepoda) of the boreal/tropical transition zone in the Russian Far East: A case study of species associations in three large lakes
Lucek et al. Effects of interspecific gene flow on the phenotypic variance–covariance matrix in Lake Victoria Cichlids
Yue et al. A descriptive analysis of human rabies in mainland China, 2005–2020

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant